183 related articles for article (PubMed ID: 23733047)
1. Differences in gene expression profiles and carcinogenesis pathways involved in cisplatin resistance of four types of cancer.
Yang Y; Li H; Hou S; Hu B; Liu J; Wang J
Oncol Rep; 2013 Aug; 30(2):596-614. PubMed ID: 23733047
[TBL] [Abstract][Full Text] [Related]
2. Candidate genes influencing sensitivity and resistance of human glioblastoma to Semustine.
Zhao Z; Liu Y; He H; Chen X; Chen J; Lu YC
Brain Res Bull; 2011 Oct; 86(3-4):189-94. PubMed ID: 21807073
[TBL] [Abstract][Full Text] [Related]
3. Microarray analysis revealed dysregulation of multiple genes associated with chemoresistance to As(2)O(3) and increased tumor aggressiveness in a newly established arsenic-resistant ovarian cancer cell line, OVCAR-3/AsR.
Ong PS; Chan SY; Ho PC
Eur J Pharm Sci; 2012 Feb; 45(3):367-78. PubMed ID: 22178533
[TBL] [Abstract][Full Text] [Related]
4. Identification and functional analysis of genes which confer resistance to cisplatin in tumor cells.
Wu ZZ; Lu HP; Chao CC
Biochem Pharmacol; 2010 Jul; 80(2):262-76. PubMed ID: 20361941
[TBL] [Abstract][Full Text] [Related]
5. Expression microarray analysis reveals genes associated with in vitro resistance to cisplatin in a cell line model.
Watson MB; Lind MJ; Smith L; Drew PJ; Cawkwell L
Acta Oncol; 2007; 46(5):651-8. PubMed ID: 17562441
[TBL] [Abstract][Full Text] [Related]
6. Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray.
Sakamoto M; Kondo A; Kawasaki K; Goto T; Sakamoto H; Miyake K; Koyamatsu Y; Akiya T; Iwabuchi H; Muroya T; Ochiai K; Tanaka T; Kikuchi Y; Tenjin Y
Hum Cell; 2001 Dec; 14(4):305-15. PubMed ID: 11925933
[TBL] [Abstract][Full Text] [Related]
7. Topological network analysis of differentially expressed genes in cancer cells with acquired gefitinib resistance.
Lee YS; Hwang SG; Kim JK; Park TH; Kim YR; Myeong HS; Kwon K; Jang CS; Noh YH; Kim SY
Cancer Genomics Proteomics; 2015; 12(3):153-66. PubMed ID: 25977174
[TBL] [Abstract][Full Text] [Related]
8. Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells.
Cheng TC; Manorek G; Samimi G; Lin X; Berry CC; Howell SB
Cancer Chemother Pharmacol; 2006 Sep; 58(3):384-95. PubMed ID: 16404635
[TBL] [Abstract][Full Text] [Related]
9. Involvement of enhancer of zeste homolog 2 in cisplatin-resistance in ovarian cancer cells by interacting with several genes.
Wang H; Yu Y; Chen C; Wang Q; Huang T; Hong F; Zhu L
Mol Med Rep; 2015 Aug; 12(2):2503-10. PubMed ID: 25955318
[TBL] [Abstract][Full Text] [Related]
10. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
11. Association between the unfolded protein response, induced by 2-deoxyglucose, and hypersensitivity to cisplatin: a mechanistic study employing molecular genomics.
Gaddameedhi S; Chatterjee S
J Cancer Res Ther; 2009 Sep; 5 Suppl 1():S61-6. PubMed ID: 20009298
[TBL] [Abstract][Full Text] [Related]
12. Microarray analysis of gene expression profile of multidrug resistance in pancreatic cancer.
Zhao YP; Chen G; Feng B; Zhang TP; Ma EL; Wu YD
Chin Med J (Engl); 2007 Oct; 120(20):1743-52. PubMed ID: 18028764
[TBL] [Abstract][Full Text] [Related]
13. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
[TBL] [Abstract][Full Text] [Related]
14. Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines.
Zhuo L; Liu J; Wang B; Gao M; Huang A
Oncol Rep; 2013 Feb; 29(2):555-62. PubMed ID: 23229111
[TBL] [Abstract][Full Text] [Related]
15. Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients.
Akervall J; Guo X; Qian CN; Schoumans J; Leeser B; Kort E; Cole A; Resau J; Bradford C; Carey T; Wennerberg J; Anderson H; Tennvall J; Teh BT
Clin Cancer Res; 2004 Dec; 10(24):8204-13. PubMed ID: 15623595
[TBL] [Abstract][Full Text] [Related]
16. The role of c-FLIP in cisplatin resistance of human bladder cancer cells.
Lee S; Yoon CY; Byun SS; Lee E; Lee SE
J Urol; 2013 Jun; 189(6):2327-34. PubMed ID: 23313194
[TBL] [Abstract][Full Text] [Related]
17. cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistance.
Samimi G; Manorek G; Castel R; Breaux JK; Cheng TC; Berry CC; Los G; Howell SB
Cancer Chemother Pharmacol; 2005 Jan; 55(1):1-11. PubMed ID: 15378272
[TBL] [Abstract][Full Text] [Related]
18. Enhanced expression of nuclear factor I/B in oxaliplatin-resistant human cancer cell lines.
Kashiwagi E; Izumi H; Yasuniwa Y; Baba R; Doi Y; Kidani A; Arao T; Nishio K; Naito S; Kohno K
Cancer Sci; 2011 Feb; 102(2):382-6. PubMed ID: 21087353
[TBL] [Abstract][Full Text] [Related]
19. Role of microRNAs in drug-resistant ovarian cancer cells.
Sorrentino A; Liu CG; Addario A; Peschle C; Scambia G; Ferlini C
Gynecol Oncol; 2008 Dec; 111(3):478-86. PubMed ID: 18823650
[TBL] [Abstract][Full Text] [Related]
20. Acquired cisplatin resistance in the head-neck cancer cell line Cal27 is associated with decreased DKK1 expression and can partially be reversed by overexpression of DKK1.
Gosepath EM; Eckstein N; Hamacher A; Servan K; von Jonquieres G; Lage H; Györffy B; Royer HD; Kassack MU
Int J Cancer; 2008 Nov; 123(9):2013-9. PubMed ID: 18688867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
